Thus, the association of low BChE with higher CV mortality may result from a pre-existing liver disease—as metabolic liver damage and/or NASH share similar risk factors as ACS—that may modulate the course ACS and ultimately cardiac mortality. This evidence concerns the gene BCHE and metabolic dysfunction-associated steatohepatitis.